Weight-Loss Shot vs. Cigarettes: Breaking Down the 2026 Semaglutide Smoking RCT
Semaglutide, famous for weight loss, also reduced nicotine craving in a May-2026 randomized trial. Here is what the data mean for future smoking-cessation care.
Weight-Loss Shot vs. Cigarettes: Breaking Down the 2026 Semaglutide Smoking RCT
In a May 2026 JAMA Network Open randomized clinical trial, once-weekly semaglutide lowered nicotine craving and body weight in adults who smoke, though it did not cut daily cigarette counts. Below you will find the key numbers, safety signals, and what these early data mean for future smoking-cessation strategies.(jamanetwork.com)
Last updated August 2026
- Study name: “Once-Weekly Semaglutide in Adults With Daily Cigarette Use” (phase 2a)
- Published: May 26 2026, JAMA Network Open
- Participants randomized: 24 (12 semaglutide, 12 placebo)
- Dosing schedule: 0.25 mg wk 1-4 → 0.5 mg wk 5-8 → 1.0 mg wk 9
- Key finding: −0.11 reduction in craving score per week vs placebo (P = .01)
- Weight change: −5.1 % with semaglutide vs +1.6 % with placebo at week 10
- Semaglutide did not statistically lower cigarettes per day but did reduce laboratory smoking behavior in a change-score analysis.
- Weekly nicotine-craving scores fell significantly with semaglutide, pointing to central reward-pathway effects.
- Participants lost about 5 % of baseline body weight, potentially offsetting post-cessation weight gain.
- Gastrointestinal side effects were common but mostly mild; one participant discontinued.
- Larger, cessation-focused trials are needed before semaglutide can be recommended for quitting smoking.
What Did the 2026 Trial Actually Test?
The phase 2a study asked a straightforward question: can a GLP-1 receptor agonist, best known for diabetes and obesity, change smoking behavior when given alone? Investigators compared nine weeks of semaglutide injections with placebo, then measured laboratory smoking behavior, real-world cigarette counts, craving, withdrawal, and metabolic markers.(jamanetwork.com)
How Was the Trial Designed and Who Participated?
Enrollment ran from October 2022 to April 2024 at an academic medical center. Non-treatment-seeking adults who smoked ≥5 cigarettes per day were randomized 1:1. Eighty-eight percent completed the primary outcome assessment.
| Baseline Characteristics | ||
|---|---|---|
| Variable | Semaglutide (n = 12) | Placebo (n = 12) |
| Mean age, y | 44 ± 11 | 44 ± 13 |
| Female, % | 83 % | 83 % |
| Cigarettes/day | 12.0 ± 5.6 | 18.8 ± 8.6 |
| FTND dependence score | 11.9 ± 4.7 | 12.2 ± 6.5 |
| BMI, kg/m² | 35.6 ± 8.1 | 31.5 ± 5.6 |
Randomization produced some imbalance in daily cigarettes, but statistical models adjusted for baseline use.(jamanetwork.com)
Did Semaglutide Cut Cigarette Use?
The co-primary endpoints — laboratory smoking resistance and cigarettes smoked during a reinstatement paradigm — showed no significant treatment-by-time interaction (β = 0.16 and −0.08, respectively). However, a pre-specified change-score analysis found a medium effect size favoring semaglutide for fewer cigarettes smoked in the lab (d = 0.67; P = .02). Real-world cigarettes per day trended downward but was not statistically different.(jamanetwork.com)
How Much Did Semaglutide Curb Nicotine Craving?
Weekly craving scores on the Brief Questionnaire of Smoking Urges decreased more sharply with semaglutide (β = −0.11 points per week; 95 % CI, −0.20 to −0.03; P = .01). Participants also reported higher self-efficacy to resist smoking by month 2.(jamanetwork.com)
| Key Week-10 Outcomes | |||
|---|---|---|---|
| Measure | Semaglutide Δ | Placebo Δ | P Value |
| Craving score (units) | −1.8 ± 0.6 | −0.4 ± 0.7 | .01 |
| Cigarettes/day | −2.1 ± 3.4 | −1.7 ± 4.0 | .72 |
| Laboratory cigarettes (count) | −2.3 ± 1.1 | −0.8 ± 1.3 | .02 |
Were There Weight or Metabolic Benefits?
Semaglutide recipients lost a mean 5.1 % of baseline body weight over ten weeks, while placebo participants gained 1.6 %. HbA1c also fell modestly in the active arm. Such metabolic gains may counteract the post-cessation weight gain that deters many smokers from quitting.(jamanetwork.com)
What Side Effects Showed Up?
As expected from the Wegovy prescribing information, mild to moderate gastrointestinal events (nausea, vomiting, and diarrhea) were most common. One participant discontinued because of nausea. No severe hypoglycemia, pancreatitis, or thyroid cancers were reported during the short follow-up.(dailymed.nlm.nih.gov)
Could GLP-1s Fit Into Future Smoking-Cessation Plans?
These findings line up with earlier signals from an exenatide-plus-nicotine-patch pilot that improved 4-week abstinence rates.(pubmed.ncbi.nlm.nih.gov) Together with evidence that semaglutide may dampen alcohol cravings , GLP-1s appear to modulate common reward pathways. Still, standard first-line options — nicotine replacement, varenicline, and bupropion — have decades of evidence, defined quit protocols, and lower cost. Until larger cessation-driven GLP-1 trials report, semaglutide should be viewed as experimental for smoking.
Trying to quit now?
- If you want proven odds of abstinence today, stick with FDA-approved cessation aids and behavioral counseling.
- If weight gain is your main barrier, discuss whether a GLP-1 fits alongside a traditional quit plan, preferably in a research setting.
- If you already take a GLP-1 for diabetes or obesity, ask your clinician whether dose timing might support your quit attempt.
- If cost or insurance hurdles worry you, see our guide on how to compare prescription drug prices.
When to Contact Your Healthcare Provider
- Severe or persistent nausea, vomiting, or abdominal pain
- Signs of low blood sugar such as sweating, confusion, or dizziness
- Neck swelling or a lump that could signal thyroid issues
- Yellowing of the skin or eyes (possible gallbladder or liver problems)
- Thoughts of self-harm, new or worsening depression
- Difficulty breathing or swelling of the face, lips, or tongue after an injection
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2614898. DOI:10.1001/jamanetworkopen.2026.14898.(jamanetwork.com)
- Hyer M, et al. Extended-Release Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation: A Pilot RCT. Nicotine Tob Res. 2021;23(10):1735-1742.(pubmed.ncbi.nlm.nih.gov)
- Taylor AE, et al. Targeting GLP-1 Receptors to Reduce Nicotine Use Disorder: Preclinical and Clinical Evidence. Addict Biol. 2024;29(2):e13255.(pubmed.ncbi.nlm.nih.gov)
- Wegovy (semaglutide) Prescribing Information. DailyMed. Updated May 2024. Accessed July 2026.(dailymed.nlm.nih.gov)
- NCT05530577. Once-Weekly Semaglutide in Adults Who Smoke. ClinicalTrials.gov. Accessed July 2026.(clinicaltrials.gov)
- Desai N, et al. GLP-1RAs for Nicotine Cessation in Psychiatric Populations: A Systematic Review. J Psychopharmacol. 2024;38(1):5-17.(pubmed.ncbi.nlm.nih.gov)
Frequently Asked Questions
Is semaglutide FDA-approved for smoking cessation?
No. The FDA approvals for semaglutide cover type 2 diabetes (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in certain adults. Using it to help quit smoking is investigational.
What dose was used in the 2026 trial?
Participants escalated from 0.25 mg once weekly for 4 weeks, to 0.5 mg for 4 weeks, and a single 1.0 mg dose in week 9 — lower than the 2.4 mg obesity dose.
Did participants actually try to quit smoking?
No. They were “non-treatment-seeking” smokers. The goal was to measure pharmacologic effects on craving and smoking behavior without counseling or nicotine replacement.
How soon did craving improve?
The treatment-by-time interaction reached significance by week 4 and grew larger through week 8, suggesting progressive benefit during dose escalation.
Will higher semaglutide doses work better?
Possibly, but efficacy and tolerability above 1 mg in smokers remain untested. Future trials plan to study 1.7-2.4 mg doses over longer periods.
Could tirzepatide or other dual agonists be stronger?
It is unknown. A head-to-head comparison is not yet available, although early obesity data suggest dual GIP/GLP-1 agonists produce robust CNS effects. See our comparison of CagriSema vs semaglutide vs tirzepatide .
How do I talk to my doctor about experimental uses?
Bring a copy of the study and review questions from our guide What to Ask Your Doctor Before Starting a New Medication to frame a shared-decision discussion.
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
